Review Article

Medicine that Causes Memory Loss: Risk of Neurocognitive Disorders

ABSTRACT

Medicine is one of the outstanding gifts of science to save lives. In addition to the desired therapeutic effect almost all of the medicine possesses undesire secondary effect called side effect. From the over-the-counter (OTC) aspirin to the prescription medicine on the market, all drugs come with side effects. Numerous are negligible, few are problematic, some are major, and certain are just weird.Almost any drug can cause nausea, vomiting or an upset stomach. Every medication carries some risks, although in some cases side effect are not noticeable as a result of sub-therapeutic concentration and memory loss is a very common side effect of commonly used and prescribed drugs. The memory loss is one of the prominent causes of neurocognitive disorders,especiallydementia, which is characterized by a disturbance of multiple brain functions, including memory, thinking, learning, reading calculation and judgement severe enough to reduce a person's ability to perform everyday activities. In addition to memory loss various factors as well as disorders contribute to the development of dementia. Alzheimer's disease (AD) is the most common form of neurodegenerative dementia. Including AD, frontotemporal dementia, and Lewy body dementia give rise to progressive and irreversible loss of neurons and brain functions. At present, there are no treatments for these progressive neurodegenerative disorders. Medication associated with the risk of memory loss must be taken with more precaution. Therefore, the objective of this study is to show the risk of memory loss associated with antianxiety drugs (benzodiazepines), hypolipedemic drugs (statins), antiseizure drugs (older and newer), antidepressant drugs (tricyclic antidepressants), narcotic painkillers (opioids), anti-Parkinson's drugs (dopamine agonists), antihypertension drugs (β-blockers), sleeping aids (nonbenzodiazepine sedative-hypnotics), incontinence drugs (anticholinergics and antimuscarinic) and antihistamines (first-generation).

Keywords: Memory loss; neurocognitive disorders; neurodegenerative dementia; Alzheimer's disease.

1. INTRODUCTION

Dementia is characterized by the loss of memory and other intellectual abilities that is severely enough to impede the activity of daily life [1]. Prevalence and occurrence forecasts that the number of people with dementia will continue to grow progressively. It occurs predominantly among the older people and countries in demographic alteration [2]. Statistics have shown that in 2010 globally the total number of people with dementia was 35.6 million and will be expected to almost double in each 20 years, i.e., 65.7 million in 2030 and 115.4 million in 2050 [3]. In the world every year the total number of new cases of dementia is approximately 7.7 million, indicating every four seconds one new case of dementia occurs [4].

The rate of dementia will be increased in developing countries, owing to the rapid growth in the elderly population appearing in China, India, and their South Asian and Western Pacific neighbors [5]. Europe had projected 10 million disease cases in 2010 and based on United Nation's demographic forecast in 2030 this figure will rise to 14 million [6]. Looking at these statistical data, it is visible that there is an emergent need for action. Now a days Alzheimer disease (AD) has become a leading public health concern as the world's population ages [7]. It is predicted that by 2050, people aged 60 and over will comprise 22% of the world's population with four-fifths living in Asia, Latin America or Africa [8].

Memory is a fixed set of sequencing neural networks in the brain, with a view to encode, store and consequently recall information and past experiences [9]. Neurotransmitters play an essential role for memory, learning and behavior [10]. The neurotransmitter is released at the presynaptic terminal due to a threshold action potential or graded electrical potential. The neurotransmitters travel across the synapse to bind to a postsynaptic receptor [11]. There are various types of receptors for different neurotransmitters, each neurotransmitter binds only to specific receptors on the postsynaptic membrane. When neurotransmitter binds to the receptor, change either exciting or inhibiting generated in the electrical state of the postsynaptic cell [12]. Excitatory and inhibitory postsynaptic

potentiality depends on the kind of neurotransmitter released.Postsynaptic potentials are referred excitatory if they increase the opportunity of occurring a postsynaptic action potential, and inhibitory if they decrease this opportunity. The process of neurotransmitter can be deactivated or neutralized in a number of way that lead to various disorders [13].

A healthy brain requires an enormous supply of neurotransmitters with a view to process thoughts and emotions to completest capacity. The right balance of neurotransmitters to function is also the major concern of brain [14]. It has usually been presumed that death of neurons causes damage of neurotransmitter, on the contrary an insufficient supply of neurotransmitter itself may lead to neurodegeneration with the end result being cognitive impairments (i.e., dementia). The furthermost common neurodegenerative disorders that present with dementia are Alzheimer's disease (AD), diffuse Lewy body disease (DLBD) and frontotemporal lobar degeneration (FTLD) [15]. More hurriedly progressive dementias have been seen with prion diseases, particularly Creutzfeldt-Jakob disease (CJD) [16]. AD is the most common form of dementia. In case of AD patients, acetylcholine (ACh), a neurotransmitter vital for memory and learning process, is decreased in both concentration and function [17].

The silent heroes of our brains are neurotransmitters. In order to function the brain properly , its cells must be able to communicate with each other. Most drugs that affect the central nervous system (CNS) act by altering some step in the neurotransmission process [18]. Drugs interfering the CNS may work presynaptically by affecting the production, storage, release, or termination of action of neurotransmitters. Statistics showed that every year prescription drugs cause over 100,000 deaths and cause severe side effects to another 1.9 million people that lead to hospitalization [19]. In USA adverse drug reactions (ADR) are now becoming the fourth principal cause of death [20]. More than 50 percent of the approved drugs in the United States was related with some type of adverse effect not identified before approval as stated by the Centre for Health Policy Research(CHPR) [21]. A study in 2011 conducted by the Agency for Healthcare Research and Quality (AHRQ) showed that among drugs that cuses adverse drug events seen in the hospital setting, sedatives and hypnotics were a leading source [22]. Every medication carries some risks and memory loss is a very common side effect. There are many types of OTC medicine as well as prescription drugs that cause memory loss [23]. Therefore, the intention of this study is to show the memory loss associated with the medicines.

2. NORMAL AGE-RELATED FORGETFULNESS

Populations are growing older in countries throughout the world. Sporadic lapses in memory areconsidered as a normal part of the aging process for most people, not a warning sign of serious mental decline or the onset of dementiapresented in Table 1 [24].

Table 1. Differences between typical age related memory changes and dementia [25, 26]

Normal age-related memory changes	Symptoms that may indicate dementia
Able to function independently and pursue normal activities, despite occasional memory lapses	Difficulty performing simple tasks (paying bills, dressing appropriately, washing up), forgetting how to do things that wascompleted many times
Able to recall and describe incidents of forgetfulness	Unable to recall or describe specific instances where memory loss caused problems
May pause to remember directions, but doesn't get lost in familiar places	Disoriented even in familiar places, unable to follow directions
Occasional difficulty finding the right word, but no trouble holding a conversation	Words are frequently forgotten, misused, repeats phrases and stories in the conversation
Judgment and decision-making ability the same as always	Trouble in making choices, may show poor judgment or behave in socially inappropriate ways

The memory lapses that are seen usually among older adults and normally don't consider as warning signs of dementia is given below [27]:

□ Becoming easily blurred [27]
□ Occasionally forgetting an appointment [27]
□ Entering into a room and forgetting entrance reason [27]

□ Not being able to recover information that on the tip of the tongue [27]
□ Having worry to recalling just read the information or the details of a conversation [27]
□ Suddenly forgetting where left things that uses regularly, such as keys [27]
□ Forgetting names of acquaintances or blocking one memory with a similar one, such as calling a grandson by your son's name [27]

3. AGING, NEURODEGENERATION AND COGNITIVE DISORDERS

Increasing age of the world's population leads to a high number of people suffering from cognitive disorders especially dementia [28]. Aging is greatly relatedto a number of degenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), atherosclerosis, and myocardial infarction [29]. The chances of developing dementia increase as we get older, but in early life it is possible to develop dementia. In fact before 65 years of age it is rare to get dementia. But the risk of developing AD doubles about every five years after the age of 65 [30]. It is projected that over the age of 65 dementia affects one in 14 people and one in six over the age of 80 [31]. In addition to aging several factors contribute to increase the risk of dementia, such as[32]:

□ Higher blood pressure in mid-life [32]
□ Changes to nerve cells, DNA and cell structure [32]
□ Weakening of the body's natural repair systems [32]
□ Changes in the immune system [32]
□ Increased incidence of heart disease and stroke [32]

Several studies have revealed that during life span the aging process is an outcome of progressive accumulation of harmful biochemical changes, leading to an imbalance of body regulatory systems, including hormonal, immune and neuroendocrine mechanisms [32]. It is strongly assumed that these changes can be more extreme in neurocognitive or neurodegenerative disorders. There are almost 36 million people suffering from dementia, according to the estimation of Alzheimer's disease international association (ADIA) [33]. It is projected that the number will be double every 20 years, hence in 2030 about 66 million people could be affected by dementia. At present, all over the world 26.6 million people have affected from AD and by 2050 this number could be more than 100 million [34]. Like AD the global burden of PD is also rising. In a study on the world's 10 most populous nations and Western Europe's 5 most populous nations, it was projected that the number of people with PD was raised from 4.1 to 4.6 million in 2005 by two times to 8.7 to 9.3 million in the year 2030 [35]. In Asian countries such as China, India, Indonesia, Pakistan, Bangladesh and Japan and the figure of PD patients was predicted to rise from 2.57 million in 2005 to 6.17 million in 2030 [36]. Aging is one of the most important identified risk factor for neurocognitive disorders.

4. MEDICINE WITH RISK OF MEMORY LOSS

For a long time scientiststhrough that forgetfulness and mental confusion are outcome of aging [37]. Nowadys scientists know that memory loss associated with as older get older is by no means unavoidable [38]. Certain study suggested that through the life the brain can grow new neuron and reshape their connections.Alcohol, drug addiction, chronic cigarette smoking, severe stress and or depression, vitamin B_{12} deficiency, head injuries and illnesses such as Alzheimer's disease etc. causative agents of memory loss [39]. In addition to this, many people don't understandthat many commonly used and prescribed medicines also can interfere with learning and memory process [23]. In case of few medicine it is not crystal clear, still a matter of debate and requires further research. The medicine causes that causes memory loss are given below:

4.1 Antianxiety drugs (Benzodiazepines)

Anxiety is a serious mental disturbance that everyone experiences at times [40]. It is characterized by an unpleasant state of tension, apprehensionor uneasiness[41]. Benzodiazepines are favored drugs for the treatment of the acute anxiety states to panic disorder, generalized anxiety disorder, social anxiety disorder, performance anxiety, posttraumatic stress disorder, obsessive-compulsive disorder and the extreme anxiety sometimes encountered with specific phobias, such as fear of flying. In addition to this they are also used for treating the anxiety, muscular disorders, amnesia, seizures and sleep disorders [42]. They exert their action by binding with $GABA_A$ receptor subunits to facilitate chloride channel opening and finally membrane hyperpolarization [43]. Benzodiazepine may produce

cognitive impairment like sustained attention, verbal learning and memory, psychomotor, visuo-motor and visuo-conceptual abilities due to long-term use [44]. Due to the sedative effect benzodiazepines reduce activity in key parts of the brain, including those involved in the transfer of events from short-term to long-term memory. For this reason anesthesiologists commonly used benzodiazepines for anesthesia [45].

Studies show that stoping of long-term benzodiazepine therapy causes improvement of cognitive function in the first six months,though deficits may be permanent or take longer than six months to return to baseline. Long-term benzodiazepine uses for elderly, increases the risk of cognitive impairment, but gradual withdrawal is related to improvement of cognitive functions [46]. Neuroimaging studies suggested that long-term benzodiazepine therapy causestransient changes in the brain, without any brain abnormalities. But a study establishes that benzodiazepines are connected with an increased risk of dementia and it is suggested that benzodiazepines are avoided in the elderly [47]. In fact long-term use of benzodiazepines may have analogous effect on the brain as alcohol. Benzodiazepines, in combination with antihypertensives cause dementia by affecting the cholinergic system. This type of dementia is accountable for 10 percent of patients attending memory clinics. Since a greater number of people use benzodiazepines, a small increment of memory loss might contribute significant deleterious effect of the cognitive function [48]. In a study of 1,389 people between the age of 60 to 70 years suggest that long-term use of benzodiazepines is associated with increased cognitive failure[49, 50]. Several prospective studies suggested the link between the use of benzodiazepine and its risk of cognitive impairment in the general population of various countries[50]. Examples of commonly prescribed benzodiazepines that cause memory loss are alprazolam, chlordiazepoxide, clonazepam, diazepam, flurazepam and lorazepam [51].

4.2 Hypolipedemic drugs (Statins)

In the United States coronary heart disease (CHD) is the leading cause of almost half of all deaths [52]. The prevalence of CHD is associated with increased levels of low-density lipoprotein (LDL) cholesterol and triacylglycerols and with low levels of high-density lipoprotein (HDL) cholesterol [53]. Alteration of hydroxymethylglutaryl coenzyme A (HMG-CoA) to mevalonate by HMG-CoA reductase is the rate-limiting step in hepatic cholesterol synthesis. The statins are structurally similar to HMG-CoA that competitively inhibits the enzyme, HMG-CoA reductase responsible for synthesis of cholesterol [54]. In all types of hyperlipidemias statins are effective in lowering plasma cholesterol levels. Reduction of brain levels of cholesterol is probably responsible for memory impairment and loss of other mental processes associated with statins. In fact, the human brain contains a quarter of the body's cholesterol liable for the formation of connections between nerve cells which trigger memory and learning. In addition to this demyelination of CNS nerve fibres may be result of memory impairment of statin. The study showed that may be within weeks or after several years of statin therapy the onset of cognitive impairment arises [55]. In fact the median time of onset is about six months. Examples of commonly prescribed HMG-CoA reductase inhibitors that cause memory loss are atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin [56].

In 2012, the FDA changed the labels for statins to show their increased risk for memory loss [57]. The agency has evaluated databases that record reports of bad reactions to drugs and statin clinical trials that involved assessments of cognitive function. The report about memory loss, forgetfulness and confusion span all statin products and all age groups. Overall, the symptoms were not serious and were reversible within a few weeks after the patient stopped using the statin [58].

Several research suggested the memory loss associated with statin in various countries. A review study published in 2003 showed that out of 60 case reports of statin-related memory loss available until then 36 involved simvastatin, 23 involved atorvastatin and 1 involved pravastatin [59]. The memory loss of statin was identified within first two months of statin therapy among half of these cases. Not only that recovery of memory loss was reported for 56% of patients due to withdraw [60]. In addition to this continuing statin use cause the return of memory loss. Another one study showed thecase of memory loss due to use of rosuvastatin by a 56-year old man at a dose of 10 mg/day. This short-term memory loss gradually resolved after the drug was withdrawn [56, 61].

4.3 Antidepressant drugs(Tricyclic antidepressants)

Depression is a serious disorder that affects about 14 million adults in the US each year. The lifetime incidence rate of depression in the US has been assessed to include 16 percent of adults (21 percent of women, 13 percent of men), or more than 32 million people [62]. There are many symptoms of depression these are strong feelings of sadness, desperateness and despair in addition to the inability to experience pleasure in normal activities, variations in sleep patterns and appetite, loss of energy, and suicidal thoughts. Most clinically useful antidepressant drugs potentiate, either directly or indirectly, the actions of norepinephrine and or serotonin in the brain. Antidepressants are prescribed for major depression (backup), chronic pain, obsessive-compulsive disorder (OCD), fibromyalgia, menopausal symptoms, hypnosis, smoking cessation, sedation, bulimia etc [63].

Memory problems of TCAs (tricyclic antidepressants) are due to blockage of two important neurotransmitters, serotonin and norepinephrine[64]. Serotonin is a monoamine neurotransmitter connected to emotional and motivational aspects of human behavior, including anxiety, depression, impulsivity, sexual behavior, etc. Serotonin also has an important role in cognitive functions, including memory and learning in particular by interacting with the cholinergic, glutamatergic, dopaminergic or GABAergic systems. The study suggested that receptors of the crucial brain structures are responsible for mediating aforementioned actions of serotonin [65]. Norepinephrine is a neurotransmitter in the catecholamine family that is important for attentiveness, emotions, sleeping, dreaming, learning and memory. Study shows that emotional arousal leads to release of norepineprine in the brain by activation of the locus coeruleus, resulting in the enhancement of memory [66]. About 35 percent of adults taking TCAs report some degree of memory impairment and about 54 percent report having difficulty concentrating [67]. Examples of commonly prescribed antidepressant drugs that causes memory loss are amitriptyline, clomipramine, desipramine, doxepin and imipramine[68].

4.4 Antiseizure drugs (Older and newer)

Seizure is the irregular release of cerebral neurons for limited periods. In a study show that about 10 percent of the population will have at least one seizure in their lifetime [69]. Drugs that are useful in seizure reduction accomplish this by several mechanisms, like blockade of voltage-gated channels (Na^+ or Ca^{2+}), enhancement of inhibitory GABAergic impulses, or interference with excitatory glutamate transmission. Some antiepileptic drugs seem to have multiple targets within the CNS, whereas the mechanism of action for some agents is unclear. The antiepilepsy drugs inhibit seizures but do not prevent epilepsy[70]. They are used for the treatment of generalized tonic-clonic seizures, partial seizures, absence seizures, myoclonic and atypical absence syndromes, status epilepticus, bipolar disorders, trigeminal neuralgia, neuropathic pain including postherpetic neuralgia. To treat seizures, these medications are used for long term and increasingly prescribed for nerve pain, bipolar disorder, mood disorders and mania[71].

Anticonvulsants limit seizures by reducing the flow of signals within the CNS and adversely affect cognitive function by suppressing neuronal excitability or enhancing inhibitory neurotransmission[72]. Impaired attention, vigilance and psychomotor speed are the main cognitive effects of antiseizure drugs, but secondary effects can apparent on other cognitive functions. In fact worsen cognitive dysfunction is reported for older antiseizure drugs (e.g., phenobarbital) than newer antiseizure drugs. The chance of cognitive decline is higher for phenytoin, although generally limited to visually guided motor functions[73]. Mild as well as significant difficulties could arise owing to the use of carbamazepine[74]. In addition to this, at low doses sodium valproate is sufficient for mimimum cognitive problems. Among the newer drugs high risk of cognitive dysfunction is associated with topiramate[75]. Examples of commonly prescribed antiseizure drugs that causes memory loss are acetazolamide, carbamazepine, ezogabine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, topiramate, valproic acid and zonisamide[68].

4.5 Narcotic painkillers (opioids)

Pain is a consequence of complex neurochemical processes in the nervous system that causes unpleasant feeling [76]. Management of pain is one of clinical medicine's greatest challenges. However, opioids are generally the drugs of choice for severe or chronic malignant or nonmalignant pain (i.e., rheumatoid arthritis) that may not respond well to other painkillers. Opioids

interactstereospecifically in different parts of the body including, with protein receptors on the membranes of certain cells in the CNS, on nerve terminals in the periphery and on cells of the gastrointestinal tract and other anatomical regions [77]. The main effects of the opioids are accomplished by three major receptor families such as, μ (mu), κ (kappa) and δ (delta). These drugs act by inhibiting the movement of pain signals within the CNS and by blunting one's emotional reaction to pain [78]. Both these actions are accomplished by chemical messengers that are also complicated in many aspects of cognition. Hence the use of these drugs can hamper with long- and short-term memory, particularly when used for prolonged periods of time [79]. Some common examples of prescribed opioids that produces memory loss are fentanyl, hydrocodone, hydromorphone, morphine and oxycodone [68].

4.6 Anti-Parkinson's drugs (Dopamine agonists)

The neurodegenerative condition Parkinson's disease (PD) is the most common cause of parkinsonism which is a progressive neurological disorder of muscle movement, categorized by tremors, muscular rigidity, bradykinesia (i.e., slowness in initiating and carrying out voluntary movements) and postural and gait abnormalities[80]. Over the age of 65 is the most potential periods of PD, among whom the prevalence is about 1 in 100 individuals[81]. Dopamine (D) receptor agonists exert their anti-Parkinson action by interacting with various D receptors. Including PD, these drugs are also used to treat certain pituitary tumors and restless legs syndrome (RLS). Anti-Parkinson's drugs activate signaling pathways for dopamine, a chemical messenger related in many brain functions, such as motivation, the experience of pleasure, fine motor control, learning and memory[82]. Consequently, serious side effects of anti-Parkinson's drugs include memory loss, confusion, delusions, hallucinations, drowsiness and compulsive behaviors such as overeating and gambling. Examples of some commonly prescribed dopamine agonist that causes memory loss are apomorphine, pramipexole and ropinirole[83].

4.7 Antihypertension drugs (β-blockers)

Hypertension is either a sustained systolic blood pressure (SBP) of greater than 140 mm Hg or a sustained diastolic blood pressure (DBP) of greater than 90 mm Hg [84]. Elevated blood pressure is an immensely common disorder, in the United State almost 15 percent of the population is affected (i.e., 60 million people)by hypertension [85]. Albeit many of these individuals have no symptoms, chronic hypertension (i.e., either systolic or diastolic) can lead to cerebrovascular disease (i.e., strokes), congestive heart failure, myocardial infarction and renal damage [86]. Although hypertension may arise secondary to other disease processes, over 90 percent of patients have essential hypertension, a disorder of unidentified origin affecting blood pressure-regulating mechanisms. β-blockers are suggested as first-line drug therapy for hypertension when concomitant disease is present, for example, in post myocardial infarction (MI) patients or in patients with a previous MI [87]. The β-blockers act by reducing blood pressure principally by decreasing cardiac output [88]. They may also decrease sympathetic outflow from the CNS as a result the release of renin from the kidneys is blocked, that lead to declining the formation of angiotensin II and the secretion of aldosterone. The main therapeutic effect of β -blockers are to slow the heart rate and decrease blood pressure and characteristically are prescribed for high blood pressure, hypertension, congestive heart failure, abnormal heart rhythms, arrhythmias, hypertensive emergencies [89]. They are also effective to treat chest pain (i.e., angina), migraines, tremors and, in eye drop form, definite types of glaucoma[90].

Side effcts of β-blockers are thought to cause memory problems by interfering with the action of prime chemical messengers in the brain, including norepinephrine and epinephrine. Extensive evidence supporting that norepinephrine is implicated in hippocampus based learning and memory in addition to its established peripheral actions [91].Abundant evidence indicates that epinephrine is the causative agent for emotionally arousing learning tasks after stressful stimulation. Some common examples of prescribed β -blockers that causes memory loss are atenolol, carvedilol, metoprolol, propranolol, sotalol and timolol[83].

4.8 Sleeping aids (Nonbenzodiazepine sedative-hypnotics)

Sleeping well is very essential for physical health and emotional well-being, which is considered as the barometer of the overall health [92]. In many cases it is known that, people in good health tend to

sleep well, on the contrary, those affecting from regular sleeping problems often have an underlying medical or mental health problem, it can be minor or serious. Weight gain, accidents, impaired job role and relationship are symptoms of sleep disorder [93]. Some sleep disorders can cause serious difficulties in quality of life that are enough to interfere with normal physical, mental, social and emotional functioning. Some common examples of prescribed sleeping aids are eszopicloneand and Z-drugs such as zaleplon and zolpidem. All of these groups are thought to control benzodiazepine specific subunit sites, as specific agonists of the $GABA_A$ receptors [94]. They are a group of nonbenzodiazepine drugs, but having similar effects like benzodiazepines, which are effective in the treatment of insomnia, mild anxiety and other sleep problems [95]. However, these are molecularly different from benzodiazepines, they work on many of the same brain pathways and chemical messengers, producing memory loss as well as similar serious side effects and problems with addiction and withdrawal [96]. The Z-drugs can also provoke memory loss and sometimes trigger dangerous or curious behaviors. It is supposed that the main mechanism of action of Z-drugs aremediated by α_1 hypnotic-inducing site of the $GABA_A$ receptor[83].

4.9 Incontinence drugs (Anticholinergics and antimuscarinic)

The baby boom generation grows older and consequently urgesincontinence is increasing [97].Incontinence medications are effective to mitigate symptoms of overactive bladder and reduce incidents of urge incontinence[98]. Incontinence drugs block the action of neurotransmitter, acetylcholine thatmediates multiple functions in the body[99]. Anticholinergics inhibit involuntary contractions of the muscles that control urine flow in the bladder. They also inhibit activity in the memory and learning centers in the brain. When the drugs are administered for more than a short time or used with other anticholinergic drugs then the risk of memory loss is raised[100]. Older people are predominantly susceptible to the other adverse effects of anticholinergic drugs, like constipation (which, in turn, can cause urinary incontinence), blurred vision, dizziness, anxiety, depression and hallucinations.Some common examples of prescribed anticholinergics that cause memory loss aredarifenacin, oxybutynin, solifenacin, tolterodine and trospium[83]. Several studies showed that memory loss associated due to the use of oxybutynin ER is comparable to about 10 years of cognitive aging. (i.e., transformed these people from functioning like 67 year olds to 77 year olds)[101].

4.10 Antihistamines(First-generation)

Histamine is a neurotransmitterthat mediates a wide variety of responses, such asallergic and inflammatory reactions, dilating blood vessels, gastric acid secretion, and neurotransmission in parts of the brain [102]. There are no clinical applications of histamine. Antihistamines act by acting as an antagonist of histamine (H) receptors[103]. These medications are effective in the treatment of allergic rhinitis, urticaria, severe itching, common cold, insomnia, motion sickness and extrapyramidal symptoms, dizziness, anxiety or insomnia. On account of the anticholinergic effect of these medications (i.e., prescription and over-the-counter) they inhibit the action of acetylcholine, a chemical messenger that interferes a wide range of activities in the body[104]. They also inhibit activity in the memory and learning centers in the brain, which can lead to memory loss. Some common examples of prescribed antihistamines that cause memory loss are brompheniramine, carbinoxamine, chlorpheniramine, clemastine, diphenhydramine and hydroxyzine[105].

4. CONCLUSION

Among all organisms the dominating characteristics of human being are due to the presence of the brain. From the present study it is clearly verified that commonly used as well as prescribed medicines are intensely connected with the risk of memory loss that's why younger and especially older population lead their life within the risk of neurocognitive disorders. Since medications are taken to save life, we will take the medicine, but marked accentuate should be given to the literature of the medicine to ensure safe and effective use. In addition to this,during prescribing physician should also consider the rational practices of drugs notthe promotional materials.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

REFERENCES

1. Huang P, Fang R, Li BY, Chen SD. Exercise-related changes of networks in aging and mild cognitive impairment brain. Front. Aging Neurosci.2016;8:1-2.
2. Rizzi L, Rosset I,Roriz-Cruz M. Global epidemiology of dementia: Alzheimer's and vascular types. BioMedRes Int.2014;(2014):1-3.
3. Prince M. World Alzheimer's Report 2009.Accessed 25 December 2009.Available:http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf.
4. WHO. Dementia.Accessed 25 December 2015.Available:http://www.who.int/mediacentre/factsheets/fs362/en/.
5. Trivedi JK, Sareen H, Dhyani M. Rapid urbanization - its impact on mental health: a South Asian perspective. Indian J Psy. 2008;50(3):161-165.
6. Duthey B. Alzheimer disease and other dementias. 2013. Accessed 25 December 2015. Available: http://www.who.int/medicines/areas/priority_medicines/BP6_11Alzheimer.pdf.
7. Rani K, Bajwa HS. Alzheimer'S disease: a brief quintessence medical management study. Cur Res Neurosci. 2015;5(1):20-24.
8. WHO. The world health report 2002 - reducing risks, promoting healthy life.Accessed 25 December 2015.Available: http://www.who.int/whr/2002/en/.
9. MallowJ, Bernarding J, Luchtmann M,Bethmann A,BrechmannA. Superior memorizers employ different neural networks for encoding and recall. front. SystNeurosci. 2015;9:1-5.
10. Anonymous. Synapses.Accessed 25 December 2015.Available: http://thebrain.mcgill.ca/flash/i/i_01/i_01_m/i_01_m_ana/i_01_m_ana.html.
11. Anonymous. Presynaptic and postsynaptic function and neurotransmitters.Accessed 25 December 2015.Available:https://quizlet.com/66906920/presynaptic-and-postsynaptic-function-and-neurotransmitters-flash-cards/.
12. D'Mello R, Dickenson AH. Spinal cord mechanisms of pain Br J Anaesth. 2008;101(1):8-16.
13. Purves D, Augustine GJ, Fitzpatrick D, et al., Excitatory and inhibitory postsynaptic potentials. Accessed 25 December 2015. 2001. Available: http://www.ncbi.nlm.nih.gov/books/NBK11117/.
14. Zaidel DW. Creativity, brain, and art: biological and neurological considerations. Front in HumanNeuroscience. 2013;8:1-6.
15. Josephs KA, Ahlskog JE, Parisi JE, Boeve BF, Crum BA, Giannini C, et al.,Rapidly progressive neurodegenerative dementias. Arch Neurol. 2009;66(2):201-207.
16. Dudhatra GB, Kumar A, Modi CM, Awale MM, Patel HB, Mody SK. Transmissible spongiform encephalopathies affecting humans. ISRN Infectious Diseases. 2013;(2013):1-6.
17. Francis PT. The interplay of neurotransmitters in Alzheimer's disease.CNS Spectr. 2005;10:6-9.
18. Masson J,Sagné C, Hamon M, Mestikawy SE. Neurotransmitter transporters in the central nervous system. Pharmacological Reviews.1999;51(3):439-464.
19. Anonymous. 20 kinds of drugs that cause memory loss.Accessed 25 December 2015.Available:http://bebrainfit.com/20-medications-that-can-cause-memory-loss/.
20. Anonymous. How pharmaceuticals came to be the 4th leading cause of death in America. Accessed 25 December 2015.Available:http://www.collective-evolution.com/2013/11/20/how-pharmaceuticals-came-to-be-the-4th-leading-cause-of-death-in-america/.
21. Blackstone EA, Fuhr JP, Pociask S.The health and economic effects of counterfeit drugs. American Health & Drug Benefits. 2014;7(4):216-224.
22. Kanaan AO, Donovan JL, Duchin NP, Field TS, Tjia J, Cutrona SL, et al. Adverse drug events post-hospital discharge in older patients: types, severity, and involvement of beers criteria medications. Journal of the American Geriatrics Society. 2013;61(11):1894-1899.
23. Anonymous. Twenty meds that cause memory loss.Accessed 25 December 2015. Available: https://www.zenithherbal.com/twenty-meds-that-cause-memory-loss/.

24. Anonymous. Memory and aging.Accessed 25 December 2015.Available:https://en.wikipedia.org/wiki/Memory_and_aging#Possible_causes_of_memory_decline.
25. Anonymous. Normal aging vs dementia.Accessed 25 December 2015.Available:http://www.alzheimer.ca/en/About-dementia/What-is-dementia/Normal-aging-vs-dementia.
26. Anonymous. Alzheimer's Disease. Accessed 25 December 2015.Available:http://www.netce.com/coursecontent.php?courseid=1086.
27. Age-related memory loss. Accessed 25 December 2015.Accessed 25 December 2015.Available: http://www.helpguide.org/articles/memory/age-related-memory-loss.htm.
28. Kalaria RN, Maestre GE, Arizaga R et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. The Lancet Neurology. 2008;7(9):812-826.
29. Uttara B, Singh AV, Zamboni P, Mahajan R. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology. 20097;(1):65-74.
30. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer's disease in older adults. BMC Geriatrics. 2015;15:9.
31. van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J NeurolNeurosurg Psychiatry. 2005;76:v2-v7.
32. Anonymous. Am I at risk of developing dementia?Accessed 25 December 2015. 2001. Available: https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=102.
33. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging process and potential interventions to extend life expectancy. Clinical Interventions in Aging. 2007;2(3):401-412.
34.Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186-191.
35. Anonymous. 100 million worldwide may have alzheimer's by 2050. Accessed 25 December 2015.Available:http://consumer.healthday.com/senior-citizen-information-31/misc-aging-news-10/100 million-worldwide-may-have-alzheimer-s-by-2050-605273.html.
36. Louis CS Tan. Epidemiology of Parkinson's disease. Neurology Asia 2013; 18(3) : 231-238.
37. Anonymous. Forgetfulness: knowing when to ask for help. Accessed 25 December 2015. 2001. Accessed 25 December 2015.Available: https://www.nia.nih.gov/health/publication/forgetfulness.
38. Roberto KA, Blieszner R, McCann, BR, McPherson MC. Family triad perceptions of mild cognitive impairment. The Journals of Gerontology. 2011; 66(6):756-68.
39. Morris JC. Is Alzheimer's disease inevitable with age? Lessons from clinicopathologic studies of healthy aging and very mild Alzheimer's disease. J Clin Invest. 1999;104(9):1171-1173.
40. Anonymus. Anxiety disorders.Accessed 25 December 2015. 2001. Accessed 25 December 2015. Available:http://www.cmha.ca/mental-health/understanding-mental-illness/anxiety-disorders/.
41. Pickett KE, Wilkinson. Inequality: an underacknowledged source of mental illness and distress. The British Journal of Psychiatry. 2010;197(6):426-428.
42. Anonymous. Anxiety.Accessed 25 December 2015.Available:http://medical dictionary.thefreedictionary.com/anxiety.
43. Griffin CE, Kay, AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system–mediated effects. The Ochsner Journal, 2013;13(2):214-223.
44. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective receptor modulators? Advances in Pharmacological Sciences. 2012;(2012):1-5.
45. Susan A, Baum A, McManus C, Newman S,Wallston K, Weinman J, et al., Cambridge handbook of psychology, health and medicine. 2nd ed. UK: Cambridge University Press; 2007.

508 46. SaariTI, Uusi-Oukari M, Ahonen J, OlkkolaKT. Enhancement of GABAergic activity:
509 neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology.
510 Pharmacological Reviews.2011;63(1):243-247.
511 47. Gallagher HC. Addressing the issue of chronic, inappropriate benzodiazepine use: how can
512 pharmacists play a role? Pharmacy. 2013;1(2):65-93.
513 48. Beverly Merz. Benzodiazepine use may raise risk of Alzheimer's disease. Accessed 25 December
514 2015. Available:http://www.health.harvard.edu/blog/benzodiazepine-use-may-raise-risk-
515 alzheimers-disease-201409107397.
516 49. Anonymus. Warning- these sleep and anxiety drugs may cause dementia. Accessed 25
517 December 2015. Available: http://www.progressivehealth.com/insomnia-anxiety-drugs-linked-to-
518 dementia.htm.
519 50. Sabrina P, Carole D, Annick A. Long-term benzodiazepine use and cognitive decline in the elderly:
520 the epidemiology of vascular aging study. Journal of Clinical Psychopharmacology.2002;22(3):285-
521 293.
522 51. MerzB. Benzodiazepine use may raise risk of Alzheimer's disease. Accessed 25 December 2015.
523 Available: http://www.health.harvard.edu/blog/benzodiazepine-use-may-raise-risk-alzheimers-
524 disease-201409107397.
525 52. Mosca L, Barrett-Connor E, Wenger NK. Sex/Gender differences in cardiovascular disease
526 prevention what a difference a decade makes. Circulation. 2011;124:2145-2154.
527 53. CM Ballantyne, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR,Kjekshus J. Influence of low high-
528 density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and
529 response to simvastatin therapy in 4S. Circulation.2001;104:3046-3051.
530 54. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al., Pharmacological
531 actions of statins: a critical appraisal in the management of cancer. Pharmacological
532 Reviews.2012;64(1):102-146.
533 55. Langa KM, Foster NL, Larson EB. Mixed dementiaemerging concepts and therapeutic
534 implications.JAMA. 2004;292(23):2901-2908.
535 56. Chase B. Memory loss and statins. Accessed 25 December 2015.
536 Available:http://www.progressivehealth.com/is-statin-related-memory-loss-common.htm.
537 57.Mercola. Statin drugs create over 60,000 new diabetics each year. Accessed 25 December 2015.
538 Available:http://articles.mercola.com/sites/articles/archive/2012/05/06/fda-warning-on-
539 statins.aspx.
540 58. Anonymous. FDA expands advice on statin risks. Accessed 25 December 2015. 2001. Available:
541 http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm.
542 59. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of
543 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-880.
544 60. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA
545 reductase inhibitors on cognition in patients with alzheimer's dementia: a prospective withdrawal
546 and rechallenge pilot study. The American Journal of Geriatric Pharmacotherapy. 2012;10(5):296-
547 300.
548 61. Anonymous. Statins and memory loss: Is there reason to worry? Accessed 25 December 2015.
549 Available: http://www.cbsnews.com/news/statins-and-memory-loss-should-you-worry/.
550 62. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Archives
551 of General Psychiatry. 2007;64(3):327-37.
552 63. Katzung BG, Masters B, Trevor AJ. Basic and clinical pharmacology. 12th ed. New York: McGraw
553 Hill; 2012.
554 64. Anonymous. How Antidepressant and antipsychotic medications work. Accessed 25 December
555 2015. Available:http://www.heretohelp.bc.ca/visions/medications-vol4/how-antidepressant-and
556 antipsychotic-medications-work#sthash.Bah5QijL.dpuf.
557 65. BerumenLC, RodríguezA, MilediR, García-AlcocerG. Serotonin receptors in hippocampus. The
558 Scientific World Journal.2012;(2012):1-15.

559 66. Tully K, Bolshakov VY. Review Emotional enhancement of memory: how norepinephrine enables
560 synaptic plasticity. Molecular Brain. 2010;3(15):1-7.
561 67. Clark M. Blood pressure, your heart, & your brain. Available:http://naturalbiohealth.com/blood-
562 pressure-your-heart-your-brain/.
563 68. Anonymous. Drugs that may cause memory loss.Accessed 25 December 2015.
564 Available:http://www.deandraper.com/blog/bid/103588/Drugs-That-May-Cause-Memory-Loss.
565 69. Saras A, Tanouye MA. Mutations of the calcium channel gene cacophony suppress seizures
566 in drosophila. PLoS Genet. 2016;12(2):1-3.
567 70. Wahab A. Difficulties in treatment and management of epilepsy and challenges in new drug
568 development. Pharmaceuticals. 2010;3(7):2090-2110.
569 71. PanayiotopoulosCP. Typical absence seizures and their treatment.Arch Dis Child. 1999;81:351-
570 355.
571 72. BansalP, Kaur R, Gupta V, Kumar S,Kaur RP. Is there any scientific basis of hawan to be used in
572 epilepsy-prevention/cure? J Epilepsy Res. 2015; 5(2): 33-45.
573 73. You SJ. Cognitive function of idiopathic childhood epilepsy.Korean J Pediatr. 2012; 55(5):159-
574 163.
575 74. EddyCM,RickardsHE,CavannaAE. The cognitive impact of antiepileptic
576 drugs.TherAdvNeurolDisord. 2011 Nov; 4(6): 385–407.
577 75. Sommer BR, Mitchell EL, Wroolie TE. Topiramate: effects on cognition in patients with epilepsy,
578 migraine headache and obesity. TherAdvNeurolDisord. 2013;6(4):211-227.
579 76. Garland EL. Pain processing in the human nervous system: a selective review of nociceptive and
580 biobehavioral pathways. Prim Care. 2012;39(3):561-571.
581 77.Kahan M, Srivastava A, Wilson L,Mailis-Gagnon A, Midmer D. Opioids for managing chronic non-
582 malignant pain Safe and effective prescribing. Can Fam Physician. 2006;52(9):1091-1096.
583 78. Davis MP. Drug management of visceral pain: concepts from basic research. Pain Research and
584 Treatment. 2012;2012:1-9.
585 79. Mathew PJ, Mathew JL. Assessment and management of pain in infants. Postgrad Med J 2003;
586 79:438-443.
587 80. Oung QW, Muthusamy H, Lee HL, Basah SN, Yaacob S, Lee MSCH. Technologies for assessment
588 of motor disorders in parkinson's disease: a review. Sensors. 2015;15(9):21710-21715.
589 81. Alves G, Forsaa EB, Pedersen KF, Gjerstad MD, Larsen JP. Epidemiology of Parkinson's
590 disease. Journal of Neurology. 2008;255(5):18-32.
591 82. Blum K, Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, et al.Neurogenetics and
592 Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical
593 Ramifications as a Function of Molecular Neurobiological Mechanisms. J Addict Res Ther.
594 2012;3:139.
595 83. Neel AB. Caution! these 10 drugs can cause memory loss. Accessed 25 December 2015.Available:
596 https://lifereimagined.aarp.org/stories/41642-10-Drugs-That-May-Cause-Memory-Loss.
597 84. Pinto E. Blood pressure and ageing. Postgraduate Medical Journal. 2007;83(976):109-114.
598 85. Harvey RA, Clark MA, Finkel R, Rey JA, Whalen K. Lippincott's Illustrated reviews pharmacology.
599 5th ed. New York: Lippincott Williams & Wilkins; 2012.
600 86. Varon J, Marik PE. Clinical review: The management of hypertensive crises. Critical
601 Care, 2003;7(5):374-384.
602 87. American Diabetes Association. Treatment of hypertension in adults with diabetes.Diabetes
603 Care. 2003;26(1):s80-s82.
604 88.Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment.Vascular Health and Risk
605 Management. 2008;4(1):23-30.
606 89. Brunton L, Chabner B, Knollman B. Goodman and Gilman's the pharmacological basis of
607 therapeutics. 12th ed. New York: McGraw Hill; 2011.
608 90. Nordqvist C. Beta blockers: types, side effects, interactions. Accessed 25 December 2015.
609 Available: http://www.medicalnewstoday.com/articles/173068.php.

610 91. Dooley TP. Treating anxiety with either beta blockers or antiemetic antimuscarinic drugs: a
611 review. Mental Health in Family Medicine. 2015;11:89-99.
612 92.Martin-Biggers JT,Koenings MM, Davis KF, Byrd-Bredbenner C.An integrative review of sleep for
613 nutrition professionals.AdvNutr. 2014;5:742-759, 2014.
614 93. Gibson GJ. Obstructive sleep apnoea syndrome: underestimated and undertreated. Br Med Bull.
615 2004;72(1):49-64.
616 94. Gielen MC, Lumb MJ, Smart TG. Benzodiazepines modulate GABAA receptors by regulating the
617 preactivation step after GABA binding. The Journal of Neuroscience. 2012;32(17):5707-5715.
618 95. McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. Prim Care Companion J Clin
619 Psychiatry. 2004;6(1):9-20.
620 96. Anonymous. Marisela Carbajal. Memory Loss.Accessed 25 December 2015. Available:
621 https://prezi.com/dj6v-ueguocp/memory-loss/.
622 97. Thompson JrD. What Is Urinary Incontinence? Accessed 25 December 2015. Available:
623 http://www.everydayhealth.com/urinary-incontinence/guide/.
624 98. Anonymous. About urge incontinence (overactive bladder). Accessed 25 December 2015.
625 Available: https://www.depend.com.au/urinary-incontinence/types/urge/.
626 99. Chancellor MB, Yoshimura N. Neurophysiology of stress urinary incontinence. Reviews in
627 Urology. 2004;6(3):S19-S28.
628 100. Merz B. Common anticholinergic drugs like Benadryl linked to increased dementia risk.
629 Accessed 25 December 2015.Available: http://www.health.harvard.edu/blog/common-
630 anticholinergic-drugs-like-benadryl-linked-increased-dementia-risk-201501287667.
631 101. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence
632 for a differential effect with darifenacin.International Journal of Clinical Practice. 2008;62(11):1792-
633 1800.
634 102. Ashina K, Tsubosaka Y, Nakamura T, Omori K, Kobayashi K, Hori M et al. Histamine induces
635 vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo. PLoS
636 ONE 2015;10(7):e0132367.
637 103. Lieberman P. The role of antihistamines in the treatment of vasomotor rhinitis.World Allergy
638 Organization Journal. 2009;2:156.
639 104. Anonymous. Chronic pain support group. Accessed 25 December 2015. Available:
640 http://www.dailystrength.org/c/Chronic_Pain/forum/21298741-memory-problems.
641 105. Anonymous. 11 Medications that may cause memory loss.Accessed 25 December 2015.
642 Available: http://medlicker.com/510-11-medications-that-may-cause-memory-loss.